The Stem Cell Exosome Therapeutic Market is valued at 13.69 Million in 2022 and is predicted to reach 59.99 Million by the year 2031 at an 18.05 % CAGR during the forecast period for 2023-2031.
Exosomes are gaining popularity rapidly as a method to access the therapeutic benefits of stem cells without the complications and difficulties of delivering the cells to patients. Exosomes are sold as diagnostic devices, therapeutic agents, cosmeceuticals, research tools, and much more. The increasing prevalence of autoimmune disease, chronic inflammation, lyme disease, and other chronic degenerative diseases is expected to boost the demand for stem cell exosome therapeutic. Additionally, the emerging research activities in exosome therapeutics are likely to accelerate the market growth in upcoming years. In the last few years, the technologies related to exosomes have been mainly developed and the demand for these technologies are very useful the fields of precision medicine, liquid biopsy, and regenerative medicine. Therefore, this is further projected to enhance the adoption of stem cell exosome therapeutic. Moreover, advancements in exosome isolation and purification techniques and rising healthcare infrastructure are likely to offer lucrative growth opportunities to the global stem cell exosome therapeutic in the next few years.
Market Segmentation
The Stem Cell Exosome Therapeutics Market is a segment based on source type, application, and geography. In terms of source type, the global market is segregated into MSC, dendritic cells, umbilical MSC, plasma, and others. In 2019, the MSC or mesenchymal stem cells segment accounted for a significant share of the global stem cell exosome therapeutics market. Mesenchymal stem cells (MSCs) are one of the most commonly employed cell types as a cell-based therapy for treating human diseases. Mesenchymal stem cells are multipotent, self-renewable, easily manageable, and customarily stretchy in vitro with exceptional genomic stability. It is widely used in the treatment of degenerative and inflammatory disease offspring cells encompassing the transgene after transplantation. Mesenchymal stem cells are used to repair injured organs such as the lung, heart, and kidney. Moreover, the dendritic cells segment is anticipated to grow at the highest CAGR during the forecast period.
Based on the application, the market is segmented into precision medicine, regenerative medicine, and others. Regenerative medicine is the largest contributing category to the global stem cell exosome therapeutic market. Regenerative medicine seeks to enhance the regeneration of tissue and organs that are damaged, malfunctioning and incomplete. Stem cell therapies are promising therapeutics in this field in damaged organs such as the myocardium after heart infarction, spinal cord injury, stroke, damaged liver, and retina diseases. Mesenchymal stem cells represent a promising stem cell population for applications in regenerative medicine. Moreover, stem cell exosome therapeutic has potential applications in precision medicine.
Geographically, the global stem cell exosome therapeutic market has been segmented into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. North America dominates the global stem cell exosome therapeutic market due to the increasing number of autoimmune diseases. Additionally, the emerging research activities required for exosome therapeutics are also projected to boost the market growth. Moreover, the U.S. dominated the regional market owing to the rising preventive expenditure for healthcare and the presence of leading manufacturers of stem cell exosome therapeutics. Europe is anticipated to be the second-largest market for stem cell exosome therapeutic due to the developed healthcare sectors. Furthermore, the Asia Pacific is expected to grow at the highest CAGR with the improved healthcare services, especially in the emerging economies of Asia Pacific.
Competitive Landscape
Some major key players in the Stem Cell Exosome Therapeutic Market:
- Aegle Therapeutics,
- Brexogen,
- Cell Care Therapeutics,
- CHA Biotech Co., Ltd.,
- ExoCoBio,
- Exopharm,
- NeoProgen, Inc.,
- OmniSpirant,
- BrainStorm Cell Therapeutics Inc.,
- Novadip Biosciences,
- Unicyte AG,
- Exogenus Therapeutics,
- Everkine Corporation,
- Creative Medical Technology Holdings,
- Anjarium Biosciences,
- Capricor Therapeutics, Inc.,
- Kimera Labs,
- ReNeuron,
- Stem Cell Medicine Ltd.,
- Codiak Biosciencesare
The Stem Cell Exosome Therapeutic Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 13.69 Million |
|
Revenue Forecast In 2031 |
USD 59.99 Million |
|
Growth Rate CAGR |
CAGR of 18.05 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Source Type, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aegle Therapeutics, Brexogen, Cell Care Therapeutics, CHA Biotech Co., Ltd., ExoCoBio, Exopharm, NeoProgen, Inc., OmniSpirant, BrainStorm Cell Therapeutics Inc., Novadip Biosciences, Unicyte AG, Exogenus Therapeutics, Everkine Corporation, Creative Medical Technology Holdings, Anjarium Biosciences, Capricor Therapeutics, Inc., Kimera Labs, ReNeuron, Stem Cell Medicine Ltd., Codiak Biosciencesare |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
